– Through selective inhibition of proinflammatory transcription, p300 KAT inhibition modulates the activity and function of multiple pro-inflammatory signaling pathways that drive chronic inflammatory diseases –
– Oral presentation taking place on Monday, November 18, 2024, from 4:15 p.m. to 4:30 p.m. EST –
SAN MATEO, Calif. and CAMBRIDGE, Mass., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (NASDAQ:KRON), a company dedicated to developing small molecule therapeutics that address cancers and other diseases driven by deregulated transcription, today announced that it will present preclinical data from its p300 KAT inhibitor program for autoimmune indications at the American College of Rheumatology's annual meeting, ACR Convergence 2024, being held from November 14 to 19, 2024 in Washington, DC.
Kronos Bio is exploring the utility of a p300 KAT inhibitor for autoimmune indications given the role of interferon regulatory factor 4 (IRF4) and p300 in B cells, T cells and other immune cells. The data being presented at the meeting support the role of p300 in inflammation, and the Company remains on track to announce a development candidate for autoimmune diseases by the end of 2024.